Stocks turned green on Friday morning on hopes out of Russia, but the markets have remained at risk. Now that investors have an opportunity to look for stocks that have pulled back, 24/7 Wall St. remains on the hunt for new research ideas. Each morning of the week we review dozens of brokerage firms’ analyst research reports. Some of these analyst reports cover stocks to buy, but many of the other research reports cover stocks to sell or stocks to avoid.
These are this Friday’s top analyst upgrades, downgrades and initiations from Wall Street analysts.
Alexza Pharmaceuticals Inc. (NASDAQ: ALXA) was downgraded to Neutral from Buy at Roth Capital.
Allergan Inc. (NYSE: AGN) was raised to Outperform from Market Perform at Leerink, on the heels of the stock falling – too much of a drop according to the firm.
Ann Inc. (NYSE: ANN) was downgraded to Neutral from Buy at UBS.
Barrick Gold Corp. (NYSE: ABX) was reiterated as Buy at Goldman Sachs, but the gold giant was added to the prized Conviction Buy List with a $22 price target (versus $18.49 close).
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) was started as Overweight and with a $20 price target (versus $12.90 close) at J.P. Morgan.
Delek US Holdings, Inc. (NYSE: DK) was raised to Outperform from Market Perform at Cowen & Co.
Hibbett Sports, Inc. (NASDAQ: HIBB) was downgraded to Underperform from Neutral at Credit Suisse. Sterne Agee also downgraded Hibbett to Neutral.
Mylan, Inc. (NASDAQ: MYL) was downgraded to Sector Perform from Outperform and the price target was cut to $53 from $60 at RBC Capital Markets.
Nimble Storage, Inc. (NYSE: NMBL) was started as Outperform with a $33 price target at Wells Fargo.
NVIDIA Corp. (NASDAQ: NVDA) was raised to Buy from Hold with a $23 price target at Needham & Co.
POZEN Inc. (NASDAQ: POZN) was raised to Buy from Hold at Ascendiant Capital.
Rubicon Technology, Inc. (NASDAQ: RBCN) was downgraded to Hold from Buy and the price target was cut to $8 from $10 at Canaccord Genuity. Also, J.P. Morgan downgraded Rubicon to Neutral from Overweight, and it cut the price target to $8 from $13.
Zynga Inc. (NASDAQ: ZNGA) shares were down 8% at $2.68 in active trading on Friday morning after poor revenues and lower guidance. Multiple firms have lowered their target prices. Its price target was cut to $4 from $5 at Canaccord Genuity. Sterne Agee lowered its earnings estimates. Macquarie cut its price target to $3. Baird lowered its target to $3 from $4 in the call.
In case you missed Thursday’s top analyst upgrades and downgrades, they were in Aetna, AOL, Chesapeake, JD.Com, Skyworks, and about a dozen more.